Galderma Gets Medytox Anti-Wrinkle Injection Patent Invalidated

Galderma S.A. convinced an administrative patent tribunal that Medytox Inc.'s wrinkle treatment patent shouldn’t have been granted.

Medytox proposed changes after the Patent Trial and Appeal Board’s preliminary findings that the patent might not withstand review. But the board found the substitute claims are also unpatentable in a final written decision July 16.

Medytox’s U.S. Patent No. 10,143,728, which issued in December 2018, is for a botulinum composition that isn’t derived from animal products and has a “longer lasting effect” than other injections like Allergan Inc.‘s Botox.

The patent isn’t involved in any litigation, but Allergan and Medytox ...